June 04, 2009 - Zydus Cadila, a global healthcare provider and one of India’s leading healthcare companies, announced the filing of the IND application for ZYD1 - a novel GLP-1 agonist molecule with the DCGI. Designed and developed at the Zydus Research Centre, ZYD1 is a novel candidate in the class of antidiabetic agents known as incretin mimetics and has displayed a better efficacy and safety profile.Incretin mimetics are poised to dominate the future of anti-diabetic therapy and presents a huge opportunity in bridging unmet medical needs that still continues to dodge the treatment and care of diabetes. The new class of drugs called incretins came to the fore in May 2005 when the world’s first GLP-1 agonist was approved by the USFDA.
ZYD1 has demonstrated beneficial effects in preclinical animal models on glucose reduction, HbA1c reduction and added benefits of weight loss. ZYD1 displayed a differentiated preclinical safety profile with no nausea-like symptoms and absence of antibody generation in the preclinical studies...
...
...The Zydus Research Centre has over 20 discovery programmes ongoing with several candidates in the pre-clinical development stage focused on metabolic, cardiovascular, pain and inflammation therapeutic areas. With over 375 research professionals spearheading its research programme, Zydus has inhouse capabilities to conduct discovery research from concept to IND enabling pre-clinical development and human proof-of-concept clinical trials... [PDF] Zydus Cadila's Press Release -
